Delorean Corporation (ASX:DEL) Shares Fall: What's Driving the Decline?

Sonal Goyal

13 November 2026 02:46 PM AEDT

Delorean Corporation (ASX:DEL) Shares Fall: What's Driving the Decline?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Delorean shares were trading at $0.08 during the 13 November 2026 session, down 6.98%.
The Board confirmed financial close on the $62.1 million NSW1 Horsley Park Bioenergy Facility on 9 November 2026.
Funding includes $30.5 million of grants and $20.0 million from Westpac, with $1.4 million in firm Placement commitments.

During the Trading session on 13 November 2026, Delorean Corporation Ltd (ASX:DEL) shares were trading at $0.08, down 6.98%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Delorean is developing renewable energy projects, including the 100% owned NSW1 Horsley Park Bioenergy Facility in New South Wales. Its latest update, dated 9 November 2026, confirmed financial close on the project.

Financial close reached

The Board confirmed financial close on the $62.1 million gross project cost, following a final Investment decision announced on 8 April 2026 and execution of the project agreements. The project can now move into procurement, with construction expected to start on site in early 2027.

Offtake and Lease arrangements

A 25-year renewable gas Supply agreement with Building Products Pty Limited and a lease with The Austral Brick Co Pty Ltd, both subsidiaries of Brickworks Limited, are now active. The facility is co-located with Brickworks' operations in Horsley Park.

Funding package

The project will be funded by a $20.0 million New South Wales government grant, a $10.5 million grant from the Australian Renewable Energy Agency, $20.0 million from Westpac, $1.6 million from funds already applied to Capital costs, $8.7 million from a new Tanarra facility, R&D tax refunds and existing cash, and $1.3 million from a private share placement. Firm commitments of $1.4 million have been received for the placement.

Sector context

Bioenergy projects that produce renewable gas typically depend on government grants, long-term supply contracts and bank Debt to reach financial close. Construction and commissioning risks are managed through defined contracts and staged funding.

Risks investors are watching

The project relies on grant funding, Westpac debt and a new facility, and any delay in drawing these funds could affect construction timing. The $8.7 million component depends on several sources, including future cash. Construction is not yet under way, and the project carries completion and operating risks.

What to watch ahead

Investors will look for the procurement contracts, the start of construction in early 2027, and confirmation that the placement and grant drawdowns are complete.

Final Word

Delorean's NSW1 project has reached financial close with a funding package and supply agreements in place. The procurement and construction phase will be the next test.

FAQs

Q: What is the total cost of the NSW1 project?

A: The gross project cost is $62.1 million.

Q: When is construction expected to start?

A: Construction is expected to commence on site in early 2027.

Q: How much is the government grant?

A: The New South Wales government grant is $20.0 million, and the ARENA grant is $10.5 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.